ARA-290

Healing & recovery Research compound (not approved for human use)

Erythropoietin-derived innate repair receptor agonist peptide · also known as Cibinetide

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

ARA-290 (cibinetide) is derived from the helix B region of erythropoietin. It targets the innate repair receptor, a complex of the EPO receptor and the beta-common receptor, and has been tested in small human studies of neuropathy. It is categorized here as healing because the research concerns nerve and tissue protection and repair.

Commonly reported dosing (10 mg vial)

Reconstituted with 2 mL → 5 mg/mL.

Also sold in 16 mg vials.

Phase	Dose	Volume	U-100 units
Starting	2 mg	0.4 mL	40
Standard	4 mg	0.8 mL	80

Frequency: Once daily, subcutaneous · Half-life: Short (minutes); effects reported to outlast plasma presence

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
2 mL of bacteriostatic water is added slowly down the inside wall of the 10 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 5 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Sealed vials are commonly stored refrigerated (2-8 °C) and protected from light, or frozen (about -20 °C) for long-term storage.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen.

Commonly used within 28 days of mixing.

How it works

Binding the innate repair receptor is associated with reduced inflammatory signaling and support of cell survival in injured tissue, without the hematopoietic effects of erythropoietin.

Researched for

Studied in a phase 2b trial in sarcoidosis-associated small-fiber neuropathy, where corneal nerve fiber measures changed.
Examined in small pilot studies in sarcoidosis and type 2 diabetes neuropathy.
Investigated in animal models of nerve injury, neuritis and ischemia.

Notes

In the sarcoidosis trial, daily subcutaneous doses of 1, 4 and 8 mg were compared with placebo for 28 days; the 4 mg dose showed the clearest effect.
A small earlier pilot study gave 2 mg by IV infusion on three days a week over a four-week period.
Trial participants were a small, specific population; evidence beyond neuropathy is preclinical.
Clinical development as cibinetide appears to have stalled after trials ended around 2016; it is not approved anywhere and no active registered trials were found.